NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: COHANCE · data 2026-10-30
Cohance Lifesciences Ltd
In plain words
Price: 41.6% below its 52-week high of ₹760.8.
Delivery: 47.1% of traded shares were kept for delivery over the last 10 sessions, against 45.6% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,142 cr |
| Net profit (last 12 months) | ₹106 cr |
| Sales growth, 3 years (yearly) | 19.0% |
| Profit growth, 3 years (yearly) | -24.2% |
Smart-money activity
27/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 42.5% over the last 20 sessions vs 35.9% in the 40 before (1.18x); shares delivered per day 0.68x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 6 schemes hold it, about ₹473 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 55/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Cohance Lifesciences Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.1.
What is Cohance Lifesciences Ltd's P/E ratio?
About 161, based on the last 12 months' earnings and a price of ₹444.3 (data 2026-10-30).
What is the 52-week high and low of Cohance Lifesciences Ltd?
The 52-week high is ₹760.8 and the 52-week low is ₹266.7.
Mutual funds holding Cohance Lifesciences Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 6 schemes holding about ₹473 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Multi Asset Allocation Fund | SBI Mutual Fund | 1.10% | ₹232 cr |
| SBI MNC Fund | SBI Mutual Fund | 1.53% | ₹98 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.66% | ₹97 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 0.81% | ₹25 cr |
| SBI Balanced Hybrid Fund | SBI Mutual Fund | 1.12% | ₹22 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.54% | ₹0 cr |
Similar companies
Shilpa Medicare Limited (SHILPAMED) · Caplin Point Laboratories Limited (CAPLIPOINT) · OneSource Specialty Pharma Limited (ONESOURCE) · PFIZER LIMITED (PFIZER) · Alivus Life Sciences Ltd (ALIVUS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open COHANCE in NSE Scanner →